NFKB1 and neoplasm: The Agarwal group demonstrated that oral silibinin (200 mg/kg, 5 d/wk for 33 days) inhibited NSCLC A549 xenograft tumor growth and suppressed the systemic toxicity of co-administered doxorubicin in athymic BALB/c nu/nu mice through a mechanism likely dependent on the regulation of nuclear factor kappaB (NFκB), a key player in the chemoresistance and dose-related (acute and cumulative) toxicity of anthracyclines [32].